Search Share Prices
AZN Headlines - AstraZeneca share price: Group posts upbeat results from Lynparza trial
A late-stage trial has showed that AstraZeneca’s (LON:AZN) oncology treatment Lynparza cut risk of disease progression or death by 70 percent in patients with newly-diagnosed, advanced BRCA ...
AstraZeneca reveals trial of Lynparza drug reduces risk of ovarian cancer worsening
AstraZeneca PLC (LON:AZN) said a phase III trial of its Lynparza drug greatly showed to greatly reduce the risk of ovarian cancer worsening. Lynparza halted or reversed tumour growth in 60% of patient...
AstraZeneca (AZN) Receives Hold Rating from Shore Capital
Shore Capital restated their hold rating on shares of AstraZeneca (LON:AZN) in a research note published on Tuesday. Several other brokerages have also recently issued reports on AZN. JPMorgan Chase & ...
AstraZeneca share price: EU regulator with positive opinion for COPD therapy
A committee of the European Medicine Agency (EMA) has issued a positive opinion for AstraZeneca’s (LON:AZN) Bevespi Aerosphere treatment for chronic obstructive pulmonary disease (COPD).
Breaking: Astrazeneca (LON:AZN) “Top Pick” Rating Reaffirmed by Barclays Today; The TP is GBX 6600.00
The financial firm has just set a target price per share of GBX 6600.00 on Astrazeneca (LON:AZN) shares. This is 12.22 % from the current price. In a note revealed to clients and investors on 16 Octob...